Taysha Gene Therapies (NASDAQ:TSHA) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report released on Monday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital restated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Up 6.6 %

NASDAQ:TSHA opened at $1.94 on Monday. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $4.32. The firm has a 50-day moving average price of $1.56 and a two-hundred day moving average price of $1.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The firm has a market cap of $397.81 million, a price-to-earnings ratio of 3.08 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, equities analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC increased its position in shares of Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after buying an additional 193,046 shares during the period. Geode Capital Management LLC lifted its holdings in Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after buying an additional 682,273 shares during the period. Franklin Resources Inc. bought a new stake in Taysha Gene Therapies during the 3rd quarter valued at approximately $201,000. JPMorgan Chase & Co. grew its holdings in shares of Taysha Gene Therapies by 1.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock worth $6,033,000 after acquiring an additional 37,844 shares during the period. Finally, Quantum Private Wealth LLC raised its position in shares of Taysha Gene Therapies by 3.6% in the 4th quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company’s stock worth $1,375,000 after acquiring an additional 27,360 shares in the last quarter. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.